Lupus nephritis management guidelines compared

Nephrology Dialysis Transplantation

Volumn 31, Issue 6, 2016, Pages 904-913

  Wilhelmus, Suzanne ^a   Bajema, Ingeborg M ^a   Bertsias, George K ^b,c   Boumpas, Dimitrios T ^c,d   Gordon, Caroline ^e   Lightstone, Liz ^f   Tesar, Vladimir ^g   Jayne, David R ^h  

^a LEIDEN UNIVERSITY MEDICAL CENTER   (Netherlands)

^b UNIVERSITY OF CRETE   (Greece)

^c INSTITUTE OF COMPUTER SCIENCE   (Greece)

^d BIOMEDICAL RESEARCH FOUNDATION   (Greece)

^e UNIVERSITY OF BIRMINGHAM   (United Kingdom)

^f IMPERIAL COLLEGE LONDON   (United Kingdom)

^g CHARLES UNIVERSITY   (Czech Republic)

^h ADDENBROOKE S HOSPITAL   (United Kingdom)

Author keywords

guideline; lupus nephritis; management; systemic lupus erythematosus; treatment

Indexed keywords

ABATACEPT; ACETYLSALICYLIC ACID; ALDOSTERONE ANTAGONIST; ANGIOTENSIN ANTAGONIST; AZATHIOPRINE; CALCINEURIN INHIBITOR; CORTICOSTEROID; CYCLOPHOSPHAMIDE; CYCLOSPORIN A; GLUCOCORTICOID; METHYLPREDNISOLONE; MYCOPHENOLATE MOFETIL; MYCOPHENOLIC ACID; RENIN INHIBITOR; TACROLIMUS;

CHILD CARE; COMORBIDITY; END STAGE RENAL DISEASE; EVIDENCE BASED MEDICINE; FAMILY PLANNING; HISTOPATHOLOGY; HUMAN; KIDNEY BIOPSY; KIDNEY TRANSPLANTATION; LUPUS ERYTHEMATOSUS NEPHRITIS; MAINTENANCE THERAPY; NONHUMAN; PATIENT MONITORING; PRACTICE GUIDELINE; PRIORITY JOURNAL; PROTEINURIA; RELAPSE; REMISSION; REPEAT PROCEDURE; REVIEW; SYSTEMIC LUPUS ERYTHEMATOSUS; TREATMENT RESPONSE; VASCULAR DISEASE; CHRONIC KIDNEY FAILURE; COMPARATIVE STUDY; COMPLICATION; DISEASE MANAGEMENT; LUPUS NEPHRITIS; STANDARDS;

DISEASE MANAGEMENT; HUMANS; KIDNEY FAILURE, CHRONIC; LUPUS NEPHRITIS; PRACTICE GUIDELINES AS TOPIC;

EID: 84975148353     PISSN: 09310509     EISSN: 14602385     Source Type: Journal    
DOI: 10.1093/ndt/gfv102     Document Type: Review

References (55)

1. Bernatsky S, Boivin JF, Joseph L et al. Mortality in systemic lupus erythematosus. Arthritis Rheum 2006; 54: 2550-2557
2. Cervera R, Khamashta MA, Font J et al. Morbidity and mortality in systemic lupus erythematosus during a 10-year period: a comparison of early and late manifestations in a cohort of 1,000 patients. Medicine (Baltimore) 2003; 82: 299-308
3. Seligman VA, Lum RF, Olson JL et al. Demographic differences in the development of lupus nephritis: a retrospective analysis. Am J Med 2002; 112: 726-729
4. Somers EC, Marder W, Cagnoli P et al. Population-based incidence and prevalence of systemic lupus erythematosus: the Michigan Lupus Epidemiology and Surveillance program. Arthritis Rheumatol 2014; 66: 369-378
5. Lim SS, Bayakly AR, Helmick CG et al. The incidence and prevalence of systemic lupus erythematosus, 2002-2004: The Georgia Lupus Registry. Arthritis Rheumatol 2014; 66: 357-368
6. Bertsias GK, Tektonidou M, Amoura Z et al. Joint European League Against Rheumatism and European Renal Association-European Dialysis and Transplant Association (EULAR/ERA-EDTA) recommendations for the management of adult and paediatric lupus nephritis. Ann Rheum Dis 2012; 71: 1771-1782
7. Hahn BH, McMahon MA, Wilkinson A et al. American College of Rheumatology guidelines for screening, treatment, and management of lupus nephritis. Arthritis Care Res (Hoboken) 2012; 64: 797-808
8. Kidney Disease: Improving Global Outcomes (KDIGO) Glomerulonephritis Work Group. KDIGO clinical practice guideline for glomerulonephritis. Kidney Int Suppl 2012; 2: 139-274
9. Ruiz Irastorza G, Espinosa G, Frutos MA et al. Diagnosis and treatment of lupus nephritis. Consensus document from the systemic auto-immune disease group (GEAS) of the Spanish Society of Internal Medicine (SEMI) and Spanish Society of Nephrology (S.E.N.). Nefrologia 2012; 32 (Suppl. 1): 1-35
10. van Tellingen A, Voskuyl AE, VervloetMGet al. Dutch guidelines for diagnosis and therapy of proliferative lupus nephritis. Neth J Med 2012; 70: 199-207
11. Mina R, von Scheven E, Ardoin SP et al. Consensus treatment plans for induction therapy of newly diagnosed proliferative lupus nephritis in juvenile systemic lupus erythematosus. Arthritis Care Res (Hoboken) 2012; 64: 375-383
12. Kidney Disease: Improving Global Outcomes (KDIGO) Blood Pressure Work Group. KDIGO clinical practice guideline for the management of blood pressure in chronic kidney disease. Kidney Int Suppl 2012; 2: 337-414
13. Wakasugi D, Gono T, Kawaguchi Y et al. Frequency of class III and IV nephritis in systemic lupus erythematosus without clinical renal involvement: an analysis of predictive measures. J Rheumatol 2012; 39: 79-85
14. Christopher-Stine L, Siedner M, Lin J et al. Renal biopsy in lupus patients with low levels of proteinuria. J Rheumatol 2007; 34: 332-335
15. Weening JJ, D'Agati VD, Schwartz MM et al. The classification of glomerulonephritis in systemic lupus erythematosus revisited. J Am Soc Nephrol 2004; 15: 241-250
16. Condon MB, Lightstone L, Cairns T et al. Is rebiopsy required to identify complete remission in patients treated for lupus nephritis? J Am Soc Nephrol 2009; 20: 405A
17. Gunnarsson I, Sundelin B, Jonsdottir T et al. Histopathologic and clinical outcome of rituximab treatment in patientswith cyclophosphamide-resistant proliferative lupus nephritis. Arthritis Rheum 2007; 56: 1263-1272
18. Grootscholten C, Bajema IM, Florquin S et al. Treatment with cyclophosphamide delays the progression of chronic lesions more effectively than does treatment with azathioprine plus methylprednisolone in patients with proliferative lupus nephritis. Arthritis Rheum 2007; 56: 924-937
19. Hill GS, Delahousse M, Nochy D et al. Predictive power of the second renal biopsy in lupus nephritis: significance of macrophages. Kidney Int 2001; 59: 304-316
20. Alsuwaida A, Husain S, Alghonaim M et al. Strategy for second kidney biopsy in patients with lupus nephritis. Nephrol Dial Transplant 2012; 27: 1472-1478
21. Pagni F, Galimberti S, Goffredo P et al. The value of repeat biopsy in the management of lupus nephritis: an international multicentre study in a large cohort of patients. Nephrol Dial Transplant 2013; 28: 3014-3023
22. Kraft SW, Schwartz MM, Korbet SM et al. Glomerular podocytopathy in patients with systemic lupus erythematosus. J Am Soc Nephrol 2005; 16: 175-179
23. Mok CC, Cheung TT, Lo WH. Minimal mesangial lupus nephritis: a systematic review. Scand J Rheumatol 2010; 39: 181-189
24. Zeher M, Doria A, Lan J et al. Efficacy and safety of enteric-coated mycophenolate sodium in combination with two glucocorticoid regimens for the treatment of active lupus nephritis. Lupus 2011; 20: 1484-1493
25. Ruiz-Irastorza G, Danza A, Perales I et al. Prednisone in lupus nephritis: how much is enough? Autoimmun Rev 2014; 13: 206-214
26. Houssiau FA, Vasconcelos C, D'Cruz D et al. The 10-year follow-up data of the Euro-Lupus Nephritis Trial comparing low-dose and high-dose intravenous cyclophosphamide. Ann Rheum Dis 2010; 69: 61-64
27. Houssiau FA, Vasconcelos C, D'Cruz D et al. Immunosuppressive therapy in lupus nephritis: the Euro-Lupus Nephritis Trial, a randomized trial of low-dose versus high-dose intravenous cyclophosphamide. Arthritis Rheum 2002; 46: 2121-2131
28. The ACCESS Trial Group. Treatment of lupus nephritis with abatacept: the abatacept and cyclophosphamide combination efficacy and safety study. Arthritis Rheumatol 2014; 66: 3096-3104
29. Isenberg D, Appel GB, Contreras G et al. Influence of race/ethnicity on response to lupus nephritis treatment: the ALMS study. Rheumatology (Oxford) 2010; 49: 128-140
30. Walsh M, Solomons N, Lisk L et al. Mycophenolate mofetil or intravenous cyclophosphamide for lupus nephritis with poor kidney function: a subgroup analysis of the Aspreva Lupus Management Study. Am J Kidney Dis 2013; 61: 710-715
31. Rovin BH, Parikh SV, Hebert LA et al. Lupus nephritis: induction therapy in severe lupus nephritis-should MMF be considered the drug of choice? Clin J Am Soc Nephrol 2013; 8: 147-153
32. Dooley MA, Jayne D, Ginzler EM et al. Mycophenolate versus azathioprine as maintenance therapy for lupus nephritis. N Engl J Med 2011; 365: 1886-1895
33. Houssiau FA, D'Cruz D, Sangle S et al. Azathioprine versus mycophenolate mofetil for long-term immunosuppression in lupus nephritis: results from the MAINTAIN Nephritis Trial. Ann Rheum Dis 2010; 69: 2083-2089
34. Feng L, Deng J, Huo DM et al. Mycophenolate mofetil versus azathioprine as maintenance therapy for lupus nephritis: a meta-analysis. Nephrology (Carlton) 2013; 18: 104-110
35. Radhakrishnan J, Moutzouris DA, Ginzler EM et al. Mycophenolate mofetil and intravenous cyclophosphamide are similar as induction therapy for class V lupus nephritis. Kidney Int 2010; 77: 152-160
36. Austin HA, III, Illei GG, Braun MJ et al. Randomized, controlled trial of prednisone, cyclophosphamide, and cyclosporine in lupus membranous nephropathy. J Am Soc Nephrol 2009; 20: 901-911
37. PragaM, Barrio V, Juarez GF et al. Tacrolimusmonotherapy inmembranous nephropathy: a randomized controlled trial. Kidney Int 2007; 71: 924-930
38. Howman A, Chapman TL, Langdon MM et al. Immunosuppression for progressive membranous nephropathy: a UK randomised controlled trial. Lancet 2013; 381: 744-751
39. Ruggenenti P, Cravedi P, Chianca A et al. Rituximab in idiopathic membranous nephropathy. J Am Soc Nephrol 2012; 23: 1416-1425
40. Mosca M, Tani C, Aringer M et al. European League Against Rheumatism recommendations for monitoring patients with systemic lupus erythematosus in clinical practice and in observational studies. Ann Rheum Dis 2010; 69: 1269-1274
41. Ruiz-Irastorza G, Ramos-Casals M, Brito-Zeron P et al. Clinical efficacy and side effects of antimalarials in systemic lupus erythematosus: a systematic review. Ann Rheum Dis 2010; 69: 20-28
42. Barber CE, Geldenhuys L, Hanly JG. Sustained remission of lupus nephritis. Lupus 2006; 15: 94-101
43. Kasitanon N, Fine DM, Haas M et al. Hydroxychloroquine use predicts complete renal remission within 12 months among patients treated with mycophenolate mofetil therapy for membranous lupus nephritis. Lupus 2006; 15: 366-370
44. Gordon C, Jayne D, Pusey C et al. European consensus statement on the terminology used in the management of lupus glomerulonephritis. Lupus 2009; 18: 257-263
45. Wofsy D, Hillson JL, Diamond B. Comparison of alternative primary outcome measures for use in lupus nephritis clinical trials. Arthritis Rheum 2013; 65: 1586-1591
46. Lightstone L. The landscape after LUNAR: rituximab's crater-filled path. Arthritis Rheum 2012; 64: 962-965
47. Weidenbusch M, Rommele C, Schrottle A et al. Beyond the LUNAR trial. Efficacy of rituximab in refractory lupus nephritis. Nephrol Dial Transplant 2013; 28: 106-111
48. Jonsdottir T, Zickert A, Sundelin B et al. Long-term follow-up in lupus nephritis patients treated with rituximab-clinical and histopathological response. Rheumatology (Oxford) 2013; 52: 847-855
49. Condon MB, Ashby D, Pepper RJ et al. Prospective observational singlecentre cohort study to evaluate the effectiveness of treating lupus nephritis with rituximab and mycophenolate mofetil but no oral steroids. Ann Rheum Dis 2013; 72: 1280-1286
50. Naesens M, Kuypers DR, Sarwal M. Calcineurin inhibitor nephrotoxicity. Clin J Am Soc Nephrol 2009; 4: 481-508
51. Liu Z, Zhang H, Liu Z et al. Multitarget therapy for induction treatment of lupus nephritis: a randomized trial. Ann Intern Med 2015; 162: 18-26
52. Ostensen M, Khamashta M, Lockshin M et al. Anti-inflammatory and immunosuppressive drugs and reproduction. Arthritis Res Ther 2006; 8: 209
53. Goldstein LH, Dolinsky G, Greenberg R et al. Pregnancy outcome of women exposed to azathioprine during pregnancy. Birth Defects Res A Clin Mol Teratol 2007; 79: 696-701
54. Livingston B, Bonner A, Pope J. Differences in clinical manifestations between childhood-onset lupus and adult-onset lupus: a meta-analysis. Lupus 2011; 20: 1345-1355
55. Sundel R, Solomons N, Lisk L. Efficacy of mycophenolate mofetil in adolescent patients with lupus nephritis: evidence from a two-phase, prospective randomized trial. Lupus 2012; 21: 1433-1443